NCT02499952 · OUTCOME

Disease Assessment for Duration of Disease Response

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors · Source last updated 2022-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From the start of treatment D1 every 6 weeks for initial 18 weeks, assessed for up to 52 weeks

What was measured

Duration of disease response

Analysis population: Data for this secondary outcome measure was not collected or analyzed due to the early termination of this study.

Pembrolizumab Pembrolizumab: 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Experimental Arm	0

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

description

Duration of disease response

groups

population Description

Data for this secondary outcome measure was not collected or analyzed due to the early termination of this study.

reporting Status

POSTED

time Frame

From the start of treatment D1 every 6 weeks for initial 18 weeks, assessed for up to 52 weeks

title

Disease Assessment for Duration of Disease Response

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice